| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
8,570,000 |
| Market
Cap: |
56.82(M) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$3.54 - $10.5 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Karyopharm Therapeutics is a pharmaceutical company focused on the discovery, development, and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. Co.'s main asset, XPOVIO® (selinexor), a Selective Inhibitors of Nuclear Export compound, is indicated for use in adult patients with multiple myeloma who have received at least one prior therapy; adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
265 |
3,287 |
40,267 |
2,073,244 |
| Total Sell Value |
$1,579 |
$20,966 |
$195,587 |
$2,212,486 |
| Total People Sold |
1 |
6 |
6 |
8 |
| Total Sell Transactions |
1 |
9 |
22 |
61 |
| End Date |
2025-10-30 |
2025-07-29 |
2025-01-28 |
2024-01-29 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Abate Kristin |
Chief Accounting Officer |
• – – |
2026-01-28 |
4 |
S |
$7.03 |
$352 |
D/D |
(50) |
22,622 |
|
- |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2026-01-27 |
4 |
A |
$0.00 |
$0 |
D/D |
92 |
22,672 |
|
- |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2026-01-21 |
4 |
S |
$5.96 |
$1,579 |
D/D |
(265) |
22,580 |
|
-9% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
12,799 |
22,845 |
|
- |
|
| Macomber Lori |
EVP, CFO & Treasurer |
• – – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,650 |
54,316 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,650 |
79,506 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
43,650 |
65,075 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
114,285 |
198,331 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-10-15 |
4 |
A |
$0.00 |
$0 |
D/D |
39,682 |
67,392 |
|
- |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-10-01 |
4 |
S |
$6.30 |
$2,279 |
D/D |
(362) |
10,046 |
|
-11% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-09-15 |
4 |
S |
$6.43 |
$148 |
D/D |
(23) |
10,408 |
|
-5% |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2025-09-15 |
4 |
S |
$6.43 |
$2,623 |
D/D |
(408) |
29,390 |
|
-5% |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-09-15 |
4 |
S |
$6.43 |
$8,083 |
D/D |
(1,257) |
84,046 |
|
-5% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-09-15 |
4 |
S |
$6.43 |
$2,578 |
D/D |
(401) |
27,710 |
|
-5% |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2025-09-15 |
4 |
S |
$6.43 |
$1,505 |
D/D |
(234) |
21,425 |
|
-5% |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2025-09-15 |
4 |
S |
$6.43 |
$2,090 |
D/D |
(325) |
35,856 |
|
-5% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
46 |
10,431 |
|
- |
|
| Rangwala Reshma |
EVP & Chief Medical Officer |
• – – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
945 |
29,798 |
|
- |
|
| Paulson Richard A. |
President and CEO |
• • – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
2,800 |
85,303 |
|
- |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
888 |
28,111 |
|
- |
|
| Mano Michael |
SVP, General Counsel&Secretary |
• – – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
612 |
21,659 |
|
- |
|
| Cheng Sohanya Roshan |
EVP & Chief Commercial Officer |
• – – |
2025-09-12 |
4 |
A |
$0.00 |
$0 |
D/D |
945 |
36,181 |
|
- |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-09-03 |
4 |
S |
$6.78 |
$81 |
D/D |
(12) |
9,463 |
|
-16% |
|
| Poulton Stuart |
EVP, Chief Development Officer |
• – – |
2025-07-29 |
4 |
S |
$4.37 |
$835 |
D/D |
(191) |
27,223 |
|
-43% |
|
| Abate Kristin |
Chief Accounting Officer |
• – – |
2025-07-22 |
4 |
S |
$4.00 |
$952 |
D/D |
(238) |
9,475 |
|
-43% |
|
582 Records found
|
|
Page 1 of 24 |
|
|
0.29 (4.19%) 
